 This will be a randomized, placebo-controlled, parallel group, multicenter, Phase III study.The study aims to evaluate the Efficacy, Tolerability and Safety of Intramuscular Injections of PLX PAD for the Treatment of Subjects with Critical Limb Ischemia CLI with Minor Tissue Loss Rutherford Category 5 who are Unsuitable for Revascularization. 